Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Interleukin-8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel-containing chemotherapy
Autore:
Mayerhofer, K; Bodner, K; Bodner-Adler, B; Schindl, M; Kaider, A; Hefler, L; Zeillinger, R; Leodolter, S; Joura, EA; Kainz, C;
Indirizzi:
Univ Vienna, Sch Med, Dept Gynecol & Obstet, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 necol & Obstet, A-1090 Vienna, Austria Univ Vienna, Sch Med, Dept Med Comp Sci, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 t Med Comp Sci, A-1090 Vienna, Austria
Titolo Testata:
CANCER
fascicolo: 2, volume: 91, anno: 2001,
pagine: 388 - 393
SICI:
0008-543X(20010115)91:2<388:ISLSIP>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
FIRST-LINE CHEMOTHERAPY; PHASE I-II; MURINE MACROPHAGES; CANCER; TAXOL; CARBOPLATIN; CELLS; ANGIOGENESIS; COMBINATION; CHEMOKINES;
Keywords:
ovarian carcinoma; paclitaxel; interleukin-8; serum;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Mayerhofer, K Univ Vienna, Sch Med, Dept Gynecol & Obstet, Wahringer Gurtel 18-20, A-1090 Vienna, Austria Univ Vienna Wahringer Gurtel 18-20 Vienna Austria A-1090 ia
Citazione:
K. Mayerhofer et al., "Interleukin-8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel-containing chemotherapy", CANCER, 91(2), 2001, pp. 388-393

Abstract

BACKGROUND, Paclitaxel has been described to induce interleukin-8 (IL-8) transcription and secretion in human ovarian carcinoma cells. The objective of this study was to investigate possible clinical implications of the effect of paclitaxel on IL-8 serum levels in patients suffering from ovarian carcinoma. METHODS. Thirty-one patients with ovarian carcinoma who were treated with combination chemotherapy consisting of paclitaxel and carboplatin entered the study. IL-8 serum levels and CA 125 serum levels were detected three times for each patient directly before chemotherapy, after three cycles of chemotherapy, and after six cycles of chemotherapy. In addition, serum samplesfrom 59 healthy, age matched women were obtained. A quantitative human IL-8 immunoassay was used to determine the IL-8 serum levels. RESULTS. Seventy-eight percent of patients responded to chemotherapy, with61% achieving a complete response and 16% achieving a partial response. The median IL-8 serum level before chemotherapy was 75 pg/mL (range, 2.7-903.3 pg/mL), the level during chemotherapy was 23.75 pg/mL (range, 0.5-248.2 pg/mL), and the level after chemotherapy was 17.65 pg/mL (range, 0.6-377.0 pg/mL). The median IL-8 serum level in controls was 15.6 pg/mL (range, 1.4-106.3 pg/mL). The authors found a statistically significant decrease in bothIL-8 serum levels (P < 0.05 and P < 0.05) and CA 125 serum levels (P < 0.05 and P < 0.05) from the first to the second measurement and from the firstto the third measurement, respectively. They found no correlation between the shifts of IL-8 serum levels and CA 125 serum levels during chemotherapy. CONCLUSIONS, The authors found a significant decrease in IL-8 serum levelsin patients undergoing a paclitaxel-containing chemotherapy regimen, indicating that IL-8 possibly acts as a useful monitoring marker in patients with ovarian carcinoma. (C) 2001 American Cancer Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/07/20 alle ore 22:04:21